NanoNovus: Elan: Nanotech Investors Keep Your Eye on the Prize

<meta name='google-adsense-platform-account' content='ca-host-pub-1556223355139109'/> <meta name='google-adsense-platform-domain' content='blogspot.com'/> <style type="text/css">@import url(https://www.blogger.com/static/v1/v-css/navbar/3334278262-classic.css); div.b-mobile {display:none;} </style> </head><body><script type="text/javascript"> function setAttributeOnload(object, attribute, val) { if(window.addEventListener) { window.addEventListener('load', function(){ object[attribute] = val; }, false); } else { window.attachEvent('onload', function(){ object[attribute] = val; }); } } </script> <div id="navbar-iframe-container"></div> <script type="text/javascript" src="https://apis.google.com/js/platform.js"></script> <script type="text/javascript"> gapi.load("gapi.iframes:gapi.iframes.style.bubble", function() { if (gapi.iframes && gapi.iframes.getContext) { gapi.iframes.getContext().openChild({ url: 'https://www.blogger.com/navbar.g?targetBlogID\x3d11139315\x26blogName\x3dNanoNovus\x26publishMode\x3dPUBLISH_MODE_BLOGSPOT\x26navbarType\x3dBLUE\x26layoutType\x3dCLASSIC\x26searchRoot\x3dhttps://nanonovusblog.blogspot.com/search\x26blogLocale\x3den_US\x26v\x3d2\x26homepageUrl\x3dhttp://nanonovusblog.blogspot.com/\x26vt\x3d2440373856899155333', where: document.getElementById("navbar-iframe-container"), id: "navbar-iframe", messageHandlersFilter: gapi.iframes.CROSS_ORIGIN_IFRAMES_FILTER, messageHandlers: { 'blogger-ping': function() {} } }); } }); </script>

Thursday, March 31, 2005

Elan: Nanotech Investors Keep Your Eye on the Prize

On March 2, after Elan dropped 70 percent in one day, I encouraged nanotech investors that it was a good time to look at Elan for its NanoCrystal technology. Today, after the company’s stock dropped another 50 percent, I still believe the company’s NanoCrystal technology—while not yet a substantial portion of the company’s revenues—offers substantial long term promise. (Full disclosure: I own Elan stock).

While it is clear that Tysabri will now represent a significantly smaller share of the company’s overall future revenues, the company still has some other attractive products in its pipeline.

As I said on March 2—and I repeat now--do your own due diligence … but that’s my two cents.

Related Links:
Nano-based Drug Delivery
Starpharma "Nano" star on the rise?
Elan Good News for Nanotech Investors?
pSivida: Down Under Comapny has Big Upside Potential